Switzerland · Delayed Price · Currency is CHF Roche Holding AG Earnings Call Transcripts
Fiscal Year 2026
-
Sales grew 6% at constant exchange rates in Q1 2026, led by strong Pharma and Diagnostics performance, despite currency headwinds and China pricing reforms. Multiple regulatory filings and positive clinical data support a robust pipeline, with guidance for mid-single-digit sales and high single-digit EPS growth reaffirmed.
-
Fenebrutinib showed strong efficacy in reducing relapses and MRI disease activity in relapsing MS, with a favorable safety profile overall, though an imbalance in fatalities was noted without a clear mechanistic link. The drug is positioned for broad use across MS types, with regulatory filing planned mid-year.
-
Peak sales for Gazyva in immune-mediated diseases are projected at $2 billion, with strong Phase III ALLEGORY results in SLE showing significant efficacy and remission rates. The immunology pipeline includes innovative B-cell-targeted and complement therapies, with further upside expected as new data emerge.
-
Fenebrutinib showed non-inferiority to ocrelizumab in PPMS, with a 12% risk reduction in disability progression and strong efficacy in patients without gadolinium-enhancing lesions. Safety monitoring via biweekly liver enzyme tests was effective. It is positioned as a high-efficacy oral option for PPMS and RMS, with broad potential uptake.
Fiscal Year 2025
-
Group sales rose 7% in 2025, driven by pharma (+9%) and diagnostics (+7% ex-China), with core operating profit up 13% and IFRS net income up 58%. Pipeline momentum remains strong, with multiple positive Phase 3 readouts and 10 NMEs advancing to Phase 3, supporting upgraded guidance for 2026.
-
The phase 3 lidERA trial demonstrated that giredestrant significantly improves invasive disease-free survival and reduces recurrence risk versus standard endocrine therapy in ER+, HER2-negative early breast cancer, with a favorable safety profile. Regulatory filings are planned for next year, and the drug is expected to become a new standard of care across stage 1–3 patients.
-
Group sales grew 7% year-to-date, led by 9% growth in pharma and 1% in diagnostics, with diagnostics outside China up 7%. The late-stage pipeline advanced significantly, and core EPS guidance was raised. Key brands and new launches drove performance, while currency and China reforms remained headwinds.
-
Phase III data for vamikibart in uveitic macular edema and satralizumab in thyroid eye disease showed robust efficacy and favorable safety, with vamikibart offering a potential non-steroid alternative and satralizumab providing a differentiated safety profile. Regulatory discussions are ongoing, and further pivotal readouts are expected in 2025 and 2026.
-
Guidance was updated to extend growth expectations for the on-market portfolio through 2028, supported by a rejuvenated pipeline, disciplined R&D investment, and a robust late-stage portfolio across five core therapeutic areas. The obesity strategy is positioned for leadership, leveraging a broad, differentiated pipeline and significant manufacturing investments.
-
Group sales rose 7% year-over-year, led by 10% growth in pharma and stable diagnostics, with strong margin and EPS gains. Pipeline momentum remains high, with multiple late-stage advancements and continued cost discipline. Guidance is maintained amid ongoing geopolitical and market uncertainties.
-
Significant clinical advances were reported for bispecifics and combination regimens in DLBCL, with strong efficacy and safety data supporting regulatory filings. HEMLIBRA maintains global leadership in hemophilia A, while next-generation therapies like NXT007 and SBK8011QQ show promising efficacy and safety, with phase III trials planned.
-
Ambitious growth targets include doubling patient access and launching 75 new assays by 2030, with a focus on innovation, digital health, and decentralized care. Key launches like the Mass Spec and SBX sequencing platforms, plus a robust digital and assay pipeline, are set to drive mid to high single-digit growth.
-
Q1 2025 saw 6% group sales growth, led by pharma (+8%) and robust new product launches, while diagnostics remained flat due to China pricing reforms. Major U.S. investments, pipeline progress, and strong performance in oncology, hematology, and ophthalmology support a positive outlook, though currency headwinds and market dynamics in China and the U.S. present challenges.
-
The neurology franchise expects continued double-digit growth, with key pipeline updates including positive fenebrutinib phase II results in MS, rapid amyloid reduction by trontinemab in Alzheimer’s, and Elevidys gene therapy showing durable benefit in DMD. Trontinemab phase III is set for late 2024, and Elevidys peak sales guidance is unchanged.
-
SBX nanopore sequencing technology is positioned to disrupt the $6B NGS market with high accuracy, speed, and flexibility, supporting both research and clinical applications. The open, modular platform targets a 2026 launch, aims for broad adoption, and is designed for scalability and cost efficiency.
Fiscal Year 2024
-
Group sales rose 7% year-over-year, with base business up 9% and strong growth in both Pharma and Diagnostics. Core operating profit increased 14%, core EPS up 12% (excluding tax effects), and free cash flow surged 34%. 2025 guidance targets mid-single digit sales growth and high single digit core EPS growth.
-
The event showcased a strategic pivot to AI-driven drug discovery, highlighting Lab-in-the-Loop integration, proprietary multimodal models, and autonomous agents. Significant R&D investment supports these efforts, which are now embedded across the pipeline and therapeutic areas.
-
The neurology pipeline features several promising assets, with Trontinumab showing rapid, robust amyloid clearance and favorable safety in early Alzheimer's trials. Diagnostic advances with Elecsys blood tests support early, accurate detection. Phase III plans focus on maximizing efficacy, safety, and patient convenience.
-
Group sales grew 6% at constant exchange rates, driven by strong base business in both pharma and diagnostics, while COVID-19 effects are now negligible. Key brands and new launches fueled growth, with robust momentum expected into 2025. Currency headwinds and LOE impacts remain key risks.
-
Management outlined a focused strategy to deliver 20 transformative medicines and 75 novel diagnostics by 2030, with strong growth expected from the on-market portfolio, pipeline, and recent acquisitions. R&D Excellence and operational efficiency are driving productivity, while upcoming late-stage readouts and launches are set to sustain momentum.
-
The CBRM franchise is advancing CT-388 and CT-996, showing strong early weight loss and safety data, with phase 2 trials underway and a focus on differentiated, combination-based obesity therapies. Interim data is expected in 2025, with launches targeted for 2029+.
-
Group sales rose 5% (8% ex-COVID), with pharma and diagnostics base businesses both up 8-9%. Operating profit and core EPS grew 11% and 9% respectively, driven by strong cost control and new product launches. Guidance for mid-single-digit sales and high single-digit EPS growth is reaffirmed.
-
Vabysmo continues rapid global growth, supported by robust clinical and real-world data showing sustained efficacy, safety, and improved treatment intervals. The prefilled syringe launch and Susvimo relaunch are expected to further accelerate adoption, while a strong pipeline and digital tools reinforce leadership in ophthalmology.
-
Hematology sales grew 12% in Q1, led by Hemlibra and Polivy. STARGLO phase III data showed glofitamab GEMOX doubled median overall survival in relapsed/refractory DLBCL. Hemlibra maintains strong efficacy, safety, and patient satisfaction, with new administration options and an auto-injector in development.